sl-172154
·Code: SL-172154
sl-172154: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Shattuck Labs, Inc. (STTK) | Phase 1 |
Clinical Trials (1)
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Frequently asked questions
Who is developing sl-172154?
sl-172154 is being developed by Shattuck Labs, Inc..
How many clinical trials involve sl-172154?
BioSniper tracks 1 clinical trial involving sl-172154.
Get deeper analysis on sl-172154
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis